TGF-β1 signal pathway may contribute to rhabdomyosarcoma development by inhibiting differentiation

Cancer Science

Volumn 101, Issue 5, 2010, Pages 1108-1116

  Wang, Shouli ^a   Guo, Lingchuan ^a   Dong, Liang ^a   Guo, Lingling ^a   Li, Shigang ^a   Zhang, Jiajia ^a   Sun, Maomin ^a  

^a MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; CASPASE 3; DESMIN; KI 67 ANTIGEN; MYOD PROTEIN; MYOGENIN; SHORT HAIRPIN RNA; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA1; PROTEIN SERINE THREONINE KINASE; SMAD4 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA TYPE II RECEPTOR; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; CELL DIFFERENTIATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; GROWTH DISORDER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; DRUG ANTAGONISM; INFANT; PATHOLOGY; PHYSIOLOGY; PRESCHOOL CHILD;

ADOLESCENT; ADULT; CELL DIFFERENTIATION; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RHABDOMYOSARCOMA; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 77953227046     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01512.x     Document Type: Article

References (40)

1. Leivonen SK, Kahari VM. Transforming growth factor-beta signaling in cancer invasion and metastasis. Int J Cancer 2007, 121:2119-24.
2. Stover DG, Bierie B, Moses HL. A delicate balance: TGF-beta and the tumor microenvironment. J Cell Biochem 2007, 101:851-61.
3. Levy L, Hill CS. Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev 2006, 17:41-58.
4. Moses HL, Yang EY, Pietenpol JA. TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights. Cell 1990, 63:245-7.
5. Liu D, Black BL, Derynck R. TGF-beta inhibits muscle differentiation through functional repression of myogenic transcription factors by Smad3. Genes Dev 2001, 15:2950-66.
6. Dias P, Parham DM, Shapiro DN, Webber BL, Houghton PJ. Myogenic regulatory protein (MyoD1) expression in childhood solid tumors: diagnostic utility in rhabdomyosarcoma. Am J Pathol 1990, 137:1283-91.
7. Parham DM. The molecular biology of childhood rhabdomyosarcoma. Semin Diagn Pathol 1994, 11:39-46.
8. El-Badry OM, Minniti C, Kohn EC, Houghton PJ, Daughaday WH, Helman LJ. Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Differ 1990, 1:325-31.
9. Schweigerer L, Neufeld G, Mergia A, Abraham JA, Fiddes JC, Gospodarowicz D. Basic fibroblast growth factor in human rhabdomyosarcoma cells: implications for the proliferation and neovascularization of myoblast-derived tumors. Proc Natl Acad Sci U S A 1987, 84:842-6.
10. De Giovanni C, Landuzzi L, Frabetti F. Antisense epidermal growth factor receptor transfection impairs the proliferative ability of human rhabdomyosarcoma cells. Cancer Res 1996, 56:3898-901.
11. Bouche M, Canipari R, Melchionna R, Willems D, Senni MI, Molinaro M. TGF-beta autocrine loop regulates cell growth and myogenic differentiation in human rhabdomyosarcoma cells. FASEB J 2000, 14:1147-58.
12. Wang H, Yang GH, Bu H. Systematic analysis of the TGF-beta/Smad signalling pathway in the rhabdomyosarcoma cell line RD. Int J Exp Pathol 2003, 84:153-63.
13. Ye L, Zhang H, Zhang L. Effects of RNAi-mediated Smad4 silencing on growth and apoptosis of human rhabdomyosarcoma cells. Int J Oncol 2006, 29:1149-57.
14. Olson EN. Interplay between proliferation and differentiation within the myogenic lineage. Dev Biol 1992, 154:261-72.
15. Molenaar WM, Oosterhuis JW, Kamps WA. Cytologic " differentiation" in childhood rhabdomyosarcomas following polychemotherapy. Hum Pathol 1984, 15:973-9.
16. McAllister RM, Melnyk J, Finkelstein JZ, Adams EC, Gardner MB. Cultivation in vitro of cells derived from a human rhabdomyosarcoma. Cancer 1969, 24:520-6.
17. Segev H, Fishman B, Ziskind A, Shulman M, Itskovitz-Eldor J. Differentiation of human embryonic stem cells into insulin-producing clusters. Stem Cells 2004, 22:265-74.
18. Yang Z, MacQuarrie KL, Analau E. MyoD and E-protein heterodimers switch rhabdomyosarcoma cells from an arrested myoblast phase to a differentiated state. Genes Dev 2009, 23:694-707.
19. Wang SL, Yao HH, Guo LL. Selection of optimal sites for TGFB1 gene silencing by chitosan-TPP nanoparticle-mediated delivery of shRNA. Cancer Genet Cytogenet 2009, 190:8-14.
20. Baer M, Nilsen TW, Costigan C, Altman S. Structure and transcription of a human gene for H1 RNA, the RNA component of human RNase P. Nucleic Acids Res 1990, 18:97-103.
21. Cui CH, Uyama T, Miyado K. Menstrual blood-derived cells confer human dystrophin expression in the murine model of Duchenne muscular dystrophy via cell fusion and myogenic transdifferentiation. Mol Biol Cell 2007, 18:1586-94.
22. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002, 296:550-3.
23. Bacman D, Merkel S, Croner R, Papadopoulos T, Brueckl W, Dimmler A. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study. BMC Cancer 2007, 7:10.
24. Ye L, Zhang HY, Wang H. Effects of transforming growth factor beta 1 on the growth of rhabdomyosarcoma cell line RD. Chin Med J (Engl) 2005, 118:678-86.
25. Wang SL, Yao HH, Qin ZH. Inhibition of differentiation by transforming growthFactor ß1 in rhabdomyosarcoma cells. Chin J Clin Oncol 2007, 4:327-32.
26. Biswas S, Criswell TL, Wang SE, Arteaga CL. Inhibition of transforming growth factor-beta signaling in human cancer: targeting a tumor suppressor network as a therapeutic strategy. Clin Cancer Res 2006, 12:4142-6.
27. Friese MA, Wischhusen J, Wick W. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res 2004, 64:7596-603.
28. Schlingensiepen KH, Schlingensiepen R, Steinbrecher A. Targeted tumor therapy with the TGF-beta2 antisense compound AP 12009. Cytokine Growth Factor Rev 2006, 17:129-39.
29. Wang SL, Yao HH, Guo LL. Antisenes oligonucleotide targeting TGF-β1 abrogates tumorigenicity of rhabdomyosarcoma in vivo. Chin J Clin Oncol 2008, 5:258-62.
30. Wu SP, Theodorescu D, Kerbel RS. TGF-beta 1 is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector. J Cell Biol 1992, 116:187-96.
31. Bouche M, Senni MI, Grossi AM. TPA-induced differentiation of human rhabdomyosarcoma cells: expression of the myogenic regulatory factors. Exp Cell Res 1993, 208:209-17.
32. Braun T, Buschhausen-Denker G, Bober E, Tannich E, Arnold HH. A novel human muscle factor related to but distinct from MyoD1 induces myogenic conversion in 10T1/2 fibroblasts. EMBO J 1989, 8:701-9.
33. Malone M. Soft tissue tumours in childhood. Histopathology 1993, 23:203-16.
34. Wright WE, Sassoon DA, Lin VK. Myogenin, a factor regulating myogenesis, has a domain homologous to MyoD. Cell 1989, 56:607-17.
35. Andreasen PA, Georg B, Lund LR, Riccio A, Stacey SN. Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol 1990, 68:1-19.
36. Ricaud S, Vernus B, Duclos M. Inhibition of autocrine secretion of myostatin enhances terminal differentiation in human rhabdomyosarcoma cells. Oncogene 2003, 22:8221-32.
37. Xu Q, Wu Z. The insulin-like growth factor-phosphatidylinositol 3-kinase-Akt signaling pathway regulates myogenin expression in normal myogenic cells but not in rhabdomyosarcoma-derived RD cells. J Biol Chem 2000, 275:36750-7.
38. Keren A, Tamir Y, Bengal E. The p38 MAPK signaling pathway: a major regulator of skeletal muscle development. Mol Cell Endocrinol 2006, 252:224-30.
39. Perdiguero E, Ruiz-Bonilla V, Serrano AL, Munoz-Canoves P. Genetic deficiency of p38alpha reveals its critical role in myoblast cell cycle exit: the p38alpha-JNK connection. Cell Cycle 2007, 6:1298-303.
40. Guo H, Zhang HY, Wang SL, Ye L, Yang GH, Bu H. Smad4 and ERK2 stimulated by transforming growth factor beta1 in rhabdomyosarcoma. Chin Med J (Engl) 2007, 120:515-21.